{"id":"mizoribine-mzr","safety":{"commonSideEffects":[{"rate":null,"effect":"Leukopenia"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mizoribine is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that selectively depletes guanosine nucleotides in lymphocytes, thereby suppressing T cell and B cell proliferation. This immunosuppressive mechanism makes it useful in preventing organ transplant rejection and treating autoimmune conditions. The drug preferentially affects lymphocytes because they rely heavily on the de novo pathway of guanine nucleotide synthesis.","oneSentence":"Mizoribine inhibits inosine monophosphate dehydrogenase (IMPDH) to suppress guanine nucleotide synthesis and reduce T and B cell proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:42.049Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ transplant rejection"},{"name":"Autoimmune and inflammatory diseases"}]},"trialDetails":[{"nctId":"NCT02256150","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis","status":"COMPLETED","sponsor":"Asahi Kasei Pharma Corporation","startDate":"2014-11","conditions":"Lupus Nephritis","enrollment":250},{"nctId":"NCT02257697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome","status":"COMPLETED","sponsor":"Asahi Kasei Pharma Corporation","startDate":"2014-11","conditions":"Nephrotic Syndrome","enrollment":239}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HE-69"],"phase":"phase_3","status":"active","brandName":"Mizoribine (MZR)","genericName":"Mizoribine (MZR)","companyName":"Asahi Kasei Pharma Corporation","companyId":"asahi-kasei-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mizoribine inhibits inosine monophosphate dehydrogenase (IMPDH) to suppress guanine nucleotide synthesis and reduce T and B cell proliferation. Used for Prevention of organ transplant rejection, Autoimmune and inflammatory diseases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}